ACTRN12612000101886
Completed
Phase 1
A Randomized controled trial of Famotidine as a Radioprotector agent versus Placebo before External Beam Radiotherapy in Patients with Prostate Cancer to Reduce Radiation- induced Acute Bowel & Urinary Toxicity using RTOG Criteria
School of Paramedical Sciences, Shahid Beheshti Medical University,0 sites36 target enrollmentJanuary 20, 2012
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Prostate Cancer
- Sponsor
- School of Paramedical Sciences, Shahid Beheshti Medical University,
- Enrollment
- 36
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with Prostate Cancer Candidate for External Beam Radiotherapy
Exclusion Criteria
- •Patients with Metastatic Prostate Cancer, Patients with Kidney \& Liver dysfunction, Patients who receive any H2– Histamine receptor antagonist simultaneously, Patients with Allergic reaction in consequence of Famotidine Administration.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
The effect of famotidine on reducing the side effects of prostate cancer radiotherapyIRCT20231121060132N1Kermanshah University of Medical Sciences50
Completed
Phase 3
Clinical trial on the effectiveness of the Famotidine on symptoms of schizophrenic patientsIRCT20190707044123N1Rasht University of Medical Sciences64
Recruiting
N/A
Bioequivalence study of Famotidine SuspensioIn the present study, the products will be administered to healthy volunteers.IRCT20210519051345N44Tabriz University of Medical Sciences24
Active, Not Recruiting
Phase 2
Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19Covid-19NCT04724720Northwell Health56
Active, Not Recruiting
Phase 1
A study to test whether lasmiditan is safe and effective in the treatment of migraine with or without aura over four attacksEUCTR2018-001661-17-ESilly S.A.1,471